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Summary 
We previously identified an HLA-B8+ donor, NW, 
whose lymphoblastoid cells failed to present a B8- 
restricted epitops from the influenza A nucleoprotein 
following viral infection, although added peptlde could 
still be presented. The failure to present through HLA- 
88 following viral infection appears to be specific for 
the NP epitope. Here, we report that donor NW makes 
an HLA-B2702-restricted influenza-specific CTL re- 
sponse to an epitope in the nucleoprotein that overlaps 
the BO-restricted epitope by 8 aa. Two mechanisms for 
the failure of this cell line to present the B&restricted 
epitops following viral infection are investigated. One 
is that there is an antigen processing polymorphism 
specific to the NW cell line, so that there is either pref- 
erential generation or preferential transport of the 
82702 epitope. The other is that 88 and 82702 com- 
pete for a common peptide fragment in the ER and this 
leads to suboptlmal loading of HLA-B8. 
Introduction 
Major histocompatibility complex (MHC) class I molecules 
bind peptides, derived from intracellular protein pools, and 
display them at the cell surface for recognition by CD6+ 
cytotoxic T cells (Townsend and Bodmer, 1969). These 
peptides are generally 8-l 1 aa long and, as revealed by 
X-ray diffraction studies, are an integral part of the class 
I structure (Bjorkman et al., 1987; Garrett et al., 1989). 
The peptide binding site is a groove formed by two a heli- 
ces lying across an eight-stranded 6 sheet and it is the 
fine structure of this groove that determines the nature of 
peptides bound (Madden et al., 1991). 
Although class I molecules associate with their peptides 
in the endoplasmic reticulum (ER), they actually recruit 
these peptides from the cytosol via an active transport 
process that utilizes the TAP complex. This complex is a 
heterodimer consisting of the TAP1 and TAP2 subunits 
and is intimately involved in the assembly of class I-62- 
peptide complexes. Recent studies have shown that TAP 
not only preferentially transports peptides of appropriate 
length for class I binding (Androlewicz et al., 1993; Neefjes 
et al., 1993; Shepherd et al., 1993) it actually facilitates 
such binding by physically associating with class l-62 di- 
mers as they assemble in the ER (Ortmann et al., 1994; 
Suh et al., 1994). Human, mouse, and rat transporters 
have some peptide sequence preference, particularly re- 
garding the N and C termini as well as the penultimate C 
terminal residue (Heemels et al., 1993; Momburg et al. 
1994b; Androlewicz and Cresswell, 1994; Schumacher et 
al., 1994), but aroleforthefinespecificityof the transporter 
in antigen presentation, if any, remains to be established. 
Proteolytic processing of antigenic proteins in the cyto- 
sol precedes translocation of peptides into the ER; these 
processes however, are still ill defined. The proteasome, 
a large multisubunit cytosolic protease with multiple cleav- 
age specificities, is thought to be involved. Two protea- 
some p-type subunits, LMPP and LMP7, are encoded by 
genes in the class II region of the MHC (Brown et al., 
1991; Glynne et al., 1991; Kellyet al., 1991; Martinez and 
Monaco, 1991; Ortiz Navarrete et al., 1991). These sub- 
units are y interferon inducible (Ortiz Navarrete et al., 
1991; Yang et al., 1992) and can alter the specificity of 
the proteasome (Driscoll et al., 1993; Boes et al., 1994). 
This has suggested a role in antigen processing and pre- 
sentation for these two subunits, although transfection 
studies have shown that these subunits are not essential 
for the presentation of all antigens (Arnold et al., 1992; 
Momburg et al., 1992; Yewdell et al., 1994; Zhou et al., 
1994). 
In humans and mice, the binding specificity of the class 
I molecule is believed to be the primary determinant in 
the selection of antigenic peptides for presentation to cyto- 
toxic T lymphocytes (CTL) (Falk et al., 1990) and usually 
the presence of the restricting class I molecule alone is 
sufficient for the appropriate processing and presentation 
of a given epitope (Wallny et al., 1992; Rotzschke et al., 
1991; Lobigs and Mullbacher, 1993). It is, therefore, un- 
usual for a cell line expressing the correct class I molecule 
to fail to present an epitope restricted by that allele. In 
previous studies of antigen presentation, however, we 
identified a donor (NW) whose lymphoblastoid cells, de- 
spite having normal cell surface expression of HLA-B8, 
failed to present a known BB-restricted epitope from the 
influenza A nucleoprotein following viral infection, al- 
though exogenously added peptide was presented nor- 
mally (RowlandJones et al., 1993). Furthermore, the fail- 
ure to present through 88 in these cells appears to be 
specific for the influenza nucleoprotein epitope, since at 
least three other BB-restricted epitopes are presented nor- 
mally by these cells following viral infection (Rowland- 
Jones et al., 1993 S. R.J., unpublished data). 
In the present studies, we have investigated the molecu- 
lar basis for the unusual properties associated with B6- 
restricted antigen presentation of the NW cell line. We 
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Figure 1. Donor NW Generates a B2702Restricted Response to the 
Influenza A Nucleoprotein that Overlaps the B8 Epitope by 8 aa 
(A) The influenza A-specific CTL response from NW is 82702 re- 
stricted and maps to NP residues 381388. Influenza-specific bulk 
cultures were established from NW PBMCs using influenza A virus 
AX/31 and were tested on influenza-infected cells or cells incubated 
with peptide. Targets were either HLA matched at only 82702 (Cl R- 
82702) or at his other A and B alleles (HW-HLA-A3, A33, 68). Specific 
lysis of targets in the absence of peptide is subtracted from each value. 
Targets are (open square) CIR-B2702 plus NP 381-366, (closed 
square) Cl R-82702 plus influenza A, (closed diamond) Cl R-82702 
plus NP 381-389, (closed triangle) HW plus NP 381-388. (open trian- 
gle) HW plus influenza A, (open diamond) HW plus NP 381-389. 
(B) NP residue 380 is required for B&restricted CTL recognition. Pep 
tides were included in the assay at a final concentration of lo* M. 
The NW’B cell line was used as a target. Effecters are CTL clone HW5 
established from donor HW. Specific lysis of targets in the absence 
of peptide has been subtracted from each value. 
Figure 2. Residues 360-391 of the Influenza A Nucleoprotein 
Three human CTL epitopes mapping to this region are shown. The 
82705 epitope maps to residues 363-391, 82702 maps to 361488, 
and B8 maps to 360-366. 
establish that donor NW does, in fact, make an influenza 
A-specific CTL response directed towards an epitope in 
the nucleoprotein. This response, however, is not re- 
stricted by HLA-B8 but rather by the other B allele of the 
donor, HLA-B2702. We have mapped the 82702 epitope 
and find that it corresponds to residues 381-388, while 
the 88 epitope corresponds to residues 380-388. Since 
overlapping epitopes, particularly of this extent, could 
present difficulties for the antigen processing and presen- 
tation machinery, this suggested possible explanations for 
the failure of NW to present nucleoprotein (NP) 380-388. 
Two possible, not necessarily mutually exclusive, mecha- 
nisms are investigated. One is that there is an antigen- 
processing or selection polymorphism specific to the NW 
cell line, so that there is either preferential generation or 
preferential transport of NP 381-388. The other is that as 
B8 and 82702 assemble in the ER they compete, at the 
level of binding, for a common NP peptide fragment and 
this leads to suboptimal loading of 88. We provide evi- 
dence for the latter of these two possibilities. 
Results 
The NW Influenza-Specific CTL Response Reveals 
a Cluster of Epitopes in the Nucleoprotein 
Influenza-specific CTL were generated from donor NW 
following natural influenza A virus infection. These CTL 
recognize influenza-infected target cells that are HLA 
matched only at 62702 and fail to recognize infected target 
cells matched only at any of his other class I alleles, which 
include A3, A33, and 88 (Figure 1A). Experiments using 
B2702-matched targets and recombinant vaccinia viruses 
revealed that the NW CTLs were responding to an epitope 
in the nucleoprotein. However, this was not the previously 
described B2705-restricted peptide, NP 383-391. Instead, 
the epitope mapped to residues NP 381-388 (Figure 1A). 
NP 381-388 overlaps both the 88 and 82705 epitopes 
(Figure 2) but it is not recognized by B2705-restricted CTL 
(data not shown) nor is it recognized by BB-restricted CTL 
(see Figure 1 B). Influenza-specific CTLs were generated 
from another donor with 82702 (LY), who is not a member 
of the NW family, and these CTLs also recognize the NP 
381-388 peptide when presented by B2702-matched tar- 
get cells, demonstrating that the presentation of this epi- 
tope is not unique to NW cells (data not shown). 
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Figure 3. Cell Lines &expressing HLA-B3 and HlA-B2702 Fail to 
Present the B&Restricted Epitope Following Viral Infection 
(A) NW cells present peptide but not virus to NP-specific B&restricted 
CTL. A control B-LCL, HR. which expresses HLA-BB in combination 
with HLA-B7, is included for comparison. Effecters are CTL clone HR4 
derived from donor HR. Targets are infected with Vat-imp. Specific 
lysis of targets in the absence of peptide was lees than 3%. 
(B) Other B-LCL-expressing BE in combination with B2702 fail to pre- 
sent the B8 NP epitope following viral infection but(C) presented added 
peptide normally. Effector cells are CTL clone HW5 derived from donor 
HW and used at the E-T ratios indicated. Virally infected targets were 
infected with l-2 HAU per 100 cells of influenza A AX/31 for 1 hr and 
allowed to express viral proteins for 2.5 hr prior to the CTL assay. For 
targets with peptide added, NP 380-3B8 was included in the assay 
at a concentration of IO-’ M. Specific lysis of targets in the absence 
of peptide has been subtracted from each value. 
(D) ClR cells expressing the allelic combination of HLA-88 and HIA- 
82702 reproduce the NW phenotype. Effectors are a BErestricted 
NP-specific CTL line established from donor HR. Targets are transfec- 
tants of Cl R cells expressing either HLA-BE (BS) or HIA-B3 and 82702 
(88-82702) and were either infected with influenza A virus AX/31 as 
for (B) or incubated with peptide as for (C); (closed square) BB plus 
peptide, (open square) BE plus virus, (closed tringle) 88-82702 plus 
peptide, (open triangle) B6-82702 plus virus. Specific lysis of targets 
in the absence of peptide has been subtracted from each value. 
Figure 3A confirms the previous observation and shows surface expression of BE (RowlandJones et al., 1993, 
L. T., unpublished data). Added peptide, however, is pre- 
sented normally. In previous studies, it was established 
that there is not a generalized defect in antigen presenta- 
tion through 68 in NW cells, since at least three other 
BE-restricted epitopes are presented normally following 
viral infection(RowlandJoneset al., 1993). Thus, NW cells 
specifically fail to generate BI-NP complexes during viral 
infection. The overlapping 88 and 82702 epitopes in the 
flu nucleoprotein suggested two possible mechanisms for 
the failure of NW cells to present the B8 epitope following 
viral infection. Each mechanism depends on how epitopes 
are actually generated in the cell. One possibility is that 
the 86 and 82702 epitopes are fully processed in the cyto- 
plasm and in NW cells there is a processing or selection 
polymorphism, which either leads to preferential genera- 
tion or preferential transport of the 82702 epitope. Alterna- 
tively, a presursor fragment spanning both epitopes could 
be generated in the cytoplasm and translocated into the 
ER. Then, in cells where 88 and 82702 are simultaneously 
assembling, there could be competition for this fragment 
and this could lead to suboptimal loading of 68. A pro- 
cessing or selection polymorphism should be specific to 
NW cells, while the second possibility should extend to 
other cell lines expressing the allelic combination of B8 
and 82702. We find that three other Epstein-Barr virus 
(EBV)-transformed B lymphoblastoid cell lines (B-LCL) 
coexpressing B8 and 82702 also show a marked reduction 
in their ability to present the epitops following viral infection 
but do present added peptide normally (Figures 38 and 
3C). The HW (88,844) and PM (B8,87) B-LCL, however, 
present both viral-derived antigen and added peptide nor- 
mally (Figures 38 and 3C). In addition to HR (Figure 3A), 
HW, and PM (Figures 38 and 3C), we have tested at least 
five other EBV transformed B-LCL, which express 88 but 
not 82702, for their ability to present viral-derived antigen 
and find that they all present normally (Sutton, 1993; Row- 
landJones et al., 1993; S. R.J. and L. T., unpublished 
data). 
We also find, using transfectants of the class l-reduced 
human B cell line Cl R, that transfectants expressing B8 
in the absence of 82702 present normally following viral 
infection, while cells coexpressing 88 and 82702 present 
viral-derived antigen poorly (Figure 3D). HLA-B8 expres- 
sion as judged by cell surface staining was comparable 
between the two transfectant cell lines; for the double 
transfectant, the cell surface staining of B8 relative to that 
of 82702 was comparable to that for NW cells (data not 
shown). In all experiments, the 88-82702 transfectants 
presented peptide less well than the B8 transfectants. This 
difference, however, was not always to the extent shown 
in Figure 3D and was always insufficient to account for the 
poor presentation by virally infected targets. We conclude 
from these data that it is the presence of 82702 that leads 
to a failure to present the 88 NP epitope following viral 
infection. We tested the possibility that B2702-NP com- 
plexes serve as antagonists to the BB-restricted CTL and 
find that they do not (data not shown). 
Thus, the results show that the inability to present the 
epitope following viral infection is not due to a processing 
polymorphism associated with NW cells but, rather, since 
it depends on the combination of alleles in the cell, to 
an event occurring between the ER and the cell surface. 
Because the sequences of the 82702 and B8 NP epitopes 
are so similar, 88 and 82702 could vie for the same NP 
peptide fragment(s) as they are assembling in the ER. 
Such a fragment must contain NP residue 380, since this 
residue is essential for BB-restricted CTL recognition (see 
Figure 1 B) and should extend at least through residue 388, 
since this residue is required for optimal BB-restricted CTL 
recognition (Sutton et al., 1993). Since the TAPS prefer to 
translocate peptides of 8-l 0 aa, one candidate is the fully 
processed 88 epitope. This peptide only represents an 
N-terminal extension of one for 827 and therefore may 
well be able to bind 82702 (see below). 
NP 380-388 Can Bind 82702 
The relative ability of B8 and 82702 to bind NP 380-388 
was tested using a previously described cell lysate binding 
assay (Tussey et al., 1994). For these assays, 1251-labeled 
NP 380-388 was incubated with lysates of metabolically 
labeled Cl Rs expressing B8,82702, or 87 as an irrelevant 
class I. Class I was immunoprecipitated from the lysates 
using the human class l-specific monoclonal antibody, 
W6/32. Samples were analyzed by SDS-PAGE and then 
quantitated using a phosphoimager (see Experimental 
Procedures). Representative results are shown in Figure 
4A. We find that NP 380-388 binds B8 and 82702 compa- 
rably. 
A Lysine Substitution at Position 382 Reduces 
Binding of NP 380-388 to 82702 without 
Altering Binding to 88 
If B8 and 82702 are competing, at the level of binding, 
for NP 360-388 (or a slightly longer fragment) then an 
amino acid substitution that would reduce binding of the 
peptide to 827 without diminishing binding to B8 should 
restore 86 presentation. The sequence of NP 380-386 is 
ELRSRYWAI. The arginine at position 362 is an anchor 
for both B6 and 82702 binding. For 88, peptide elution 
studies have shown that while arginine is accepted, lysine 
is actually the preferred residue at this position (Sutton et 
al., 1993; DiBrino et al., 1994). Further, previous studies 
have shown that a lysine substitution at position 382 of 
the NP 380-388 peptide has no effect on either its ability 
to bind B8 or on CTL recognition of the peptide (Sutton 
et al., 1993; DiBrino et al., 1994). The peptide binding motif 
for both B2702 and 82705 has been determined by pool 
sequencing of endogenously bound peptides (Jardetzky 
et al., 1991; Rotzschke et al., 1994). Common to both 
motifs is the anchor of arginine at position 2 and virtually 
all of the sequenced B27-associated peptides have an 
arginine at this position (Engelhard, 1994). The role of the 
B pocket, which is identical among the 827 subtypes, in 
determining this anchor is well established (Madden et al., 
1992). Other studies with 82705 and NP 363-391 have 
shown that a lysine at P2 completely abolishes presenta- 
tion of this peptide, presumably as a result of a loss in 
binding (Colbert et al., 1993). As a first step in testing 
whether we could restore 88 presentation by reducing the 
ability of 82702 to bind the peptide, we synthesized NP 
380-368 (K) (which has a lysine substitution at residue 
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Figure 4. NP 360-366 Binds 82702 in In Vitro Binding Assays 
Binding of ‘261-labeled (A) NP 360-366 or (8) NP 360-366 (K) to 86, 
82702, or 87 in lysates of Cl Rs expressing 86, 82702, or 87. Gels 
were quantitated using a phosphoimager. For each gel, pixels con- 
tained within the peptide band were normalized to pixels contained 
in the heavy chain band and this ratio was plotted against peptide 
concentration. The graphs shown represent the average of two gels 
and the pixel ratios were within 10%-l 1% between these gels. The 
final concentration of peptide for each point is estimated to range from 
50 nM to 2 uM (see Experimental Procedures). 
382) and tested the effect of this substitution on binding 
of the peptide to 88 and 82702 using the same assay as 
for Figure 4A (Figure 48). As predicted by the binding 
specificities of the two molecules, the lysine substitution 
at position 382 has no deleterious effect on binding to 
B8, while binding to 82702 is greatly diminished by this 
substitution. 
The association of B8 or 82702 with NP 380-388 or NP 
380-388 (K) following their translocation into the ER was 
also investigated. For these assays, streptolysin O-per- 
meabilized cells were used as a means of introducing the 
peptide into the cytosol (Androlewict et al., 1993). Y- 
labeled peptide, either NP 380-388 or NP 380-388 (K), 
was introduced into the cytosol of Cl R cells expressing 
B8,82702, or 87 as an irrelevant class I molecule. Follow- 
ing translocation, cells were solubilized and the class I 
immunoprecipitated using W8/32. The level of bound pep 
tide was determined by counting in ay counter. The results 
with the Cl R transfectants show that NP 380-388 binds 
82702 and 88 comparably following its translocation into 
the ER. The lysine substitution at position 382, however, 
alters the relative ability of the peptide to bind these alleles 
following its translocation into the ER (Figure 5A). These 
assays are a function of the ability of the peptide to com- 
pete for binding to class I as well as its ability to compete 
for translocation. Thus, the lysine substitution could affect 
the efficiency of translocation or the ability of the peptide 
to bind class I, or both. Todistinguish between these possi- 
bilities, the relative ability of NP 380-388 and NP 380- 
388 (K) to compete for translocation was measured directly 
using the recently described method of Neefjes et al. 
(1993) and others (Androlewicz and Cresswell, 1994) and 
was found to be the same (Figure 58). Thus, the differ- 
ences in intracellular loading of B8 and 82702 with these 
two peptides are due to differences in the relative ability 
of the peptides to bind to HLA following their translocation 
into the ER. NW cells were included in these assays, but 
the antibody used will precipitate all class I from the cell; 
B8- and B2702-specific monoclonal antibodies, which are 
also suitable for immunoprecipitations, are not available. 
The counts recovered from NW were approximately the 
sum of the counts from Cl R 88 and Cl R 82702 for both 
peptides, so the ratio of peptide binding to B8 versus 
82702 in ClRs might actually reflect the distribution of 
the peptide between B8 and 82702 in NW cells: that is, 
NP 380-388 is evenly distributed between B8 and 82702, 
whereas NP 380-388(K) is preferentially associated with 
88. When one compares the absolute number of counts 
recovered in these assays, it would suggest that the results 
are slightly different from those with the lysate binding 
assays (see Figures 4A and 48) in that the lysine substitu- 
tion appears to enhance binding of the peptide to B8. How- 
ever, if one compares relative binding (i.e., 827 versus 
88) for the two assays the results are actually quite similar. 
For example, 82702 binding of NP 380-388 is roughly 
80%-70% that of B8 in the lysate binding assays, whereas 
it is 89% in the intracellular transport assays. 82702 bind- 
ing of NP 380-388 (K) is 10%-l 5% that of 88 in the lysate 
binding assay and 28% that of 88 in the intracellular trans- 
port assay. However, because we were looking for a sub- 
stitution that reduced the ability of B2702 to bind without 
altering 88 binding, we further tested the effects of this 
substitution on 88 binding using a third binding assay pre- 
viously described by Gao et al. (1994). Unfortunately, this 
assay could not be used for 82702, which is extremely 
difficult to fold in vitro, but the results with 88 clearly and 
reproducibly show that the lysine substitution has no effect 
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Figure 5. NP 390-398 Can Associate with 82702 Following Its Trans- 
location into the ER 
(A) Intracellular loading of ‘2JI-labeled NP 390-399 (open bars) or NP 
390-389 (K) (closed bars) in permeabilized cells of either NW or Cl Rs 
expressing 69, 82702, or 87. Counts represent the average of dupli- 
cates, which were within 10% of each other. 
(B) The lysine substitution does not affect the ability of the NP peptide 
to compete for translocation. Competition curves for (closed square) 
NP 380-399, (open square) NP 390-399 (K), and (closed diamond) NP 
391-399 are shown. The previously characterized B27#3 self-peptfde 
(open diamond) is included as a reference peptide. The percentage 
of maximum translocation (y-axis) indicates the amount of ‘“I-B27#3’ 
translocated into the ER as measured by binding to concanavalin 
A-Sepharose. 
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Figure 6. In Vitro Assembly of HLA-B9 with NP 390-399 Versus NP 
390-399 (Kj 
Metabolically labeled HLAB9 was assembled in the lysates of CHO 
cells using the various concentrations of peptide stated and then immu- 
noprecipitated. Samples were analyzed on 12% NaDodSCM-poly- 
acrylamide gels and then quantitated using a phospho-imager. Pixels 
contained in the heavy chain band were plotted against peptide con- 
centration. The NP 391-399 peptide binds B9 poorly because of its 
charged C terminus and is included as a negative control. 
on the ability of 66 to bind the peptide (Figure 6). Note 
that inclusion of NP residue 389 completely abrogates 
binding of the peptide. This residue is charged and 88 
prefers hydrophobic C termini (Sutton et al., 1993; DiBrino 
et al., 1994). In addition to these stabilization assays, we 
have also compared the titration curves for the 382R and 
382K peptides in B&restricted NP-specific CTL assays 
and find, using four different cell lines as targets, that the 
titration curves for the two peptides are virtually identical 
(data not shown). We therefore conclude that the lysine 
substitution alters the relative ability of the peptide to bind 
the two molecules by reducing its ability to bind 82702 
and, as such, may be sufficient to restore presentation 
through B8 in NW cells. 
A Lysine Substitution at Residue 382 Restores B8 
Presentation In NW Cells 
To test the hypothesis that B8 and 82702 compete for an 
NP peptide at the level of binding, recombinant vaccinias 
were generated that expressed either the wild-type NP 
sequence corresponding to residues 374-393 or this se- 
quence with a lysine substitution at residue 382. Figures 
7A-7D shows the data from four independent experiments 
using four different B8-restricted NP-specific CTL clones 
(established from two donors). Targets were NW and HW 
cells infected with either of these constructs. In all four 
experiments, peptide-pulsed HW and NW targets were 
killed comparably, and for clarity these data have been 
omitted from each graph. For lysis of the vaccinia targets, 
$$ss I Alleles Compete For Overlapping Epitopes 
50 
40 
10 
60 
A 
40 
t NW 362R 
4 NW 302K 
-A- HW 362R 
4HW 362K 
6 to 1 1 to 1 
E : T Ratio 
30 
*a 
2 
P 
A 
i 
UJ 
8 
1c 
C 
+ NW 382R 
4 NW 382K 
-A- HW 382Fl 
4HW 382K 
0 
B 
4 NW HIV Pal 
-W-NW 382R 
4NW382K 
X HW HIV Pal 
4HW362R 
-A- HW 382K 
6 to 1 2 to 1 
E : T Ratio 
60 
t NW 382R 
4 NW 362K 
-A- HW 332R 
4 HW 382K 
3 to 1 1 to 1 0.3 to 1 
E : T Ratio 
0 
D 
8 
4 to 1 1 to 1 0.25 to 1 
E : T Ratio 
Figure 7. A Lysine Substitution at NP Residue 362 Restores Presentation of Viral-Derived NP 360-366 in NW Cells 
(A-D) Targets were infected with recombinant vaccinias expressing either NP residues 374-391 without (362R) or with (362K) a lysine substitution 
at residue 362 or with HIV-Pol as an irrelevant control. The control B-LCL HW was established from the daughter of NW, who expresses 86 in 
combination with 844. Effecters are (A) CTL clone HWl9 established from donor HW, (6) CTL clone HW6 established from donor HW, (C) CTL 
clone AR3 established from donor AR, and (D) CTL clone AR1 96 established from donor AR. Targets were lysed appropriately with added peptide, 
although for clarity the data has been omitted; lysis of targets in the absence of peptide was less than 5% for all ratios in each experiment. Lysis 
of targets infected with HIV-Pol was less than 3% for (A), (C), and (D) and was omitted for clarity. 
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however, we find that lysis of NW cells infected the 382K 
construct is substantially better than for those infected 
with the wild-type 382R construct, while lysis of virally in- 
fected HW cells is comparable using the two constructs. 
Since the recombinant vaccinias encode NP residues 
374-393, it is formally possible that introduction of the 
lysine at position 382 alters processing in such a way as 
to now favor production of the B8 epitope. We feel that 
this is unlikely, since presentation through 88 is the same 
for both recombinant vaccinias in cells lacking 82702. We 
therefore interpret these results to mean that 88 and 
82702 do in fact compete, at the level of binding, for a 
common fragment in the ER. This leads to suboptimal 
loading of B8 and the subsequent poor presentation of 
viral-derived antigen. A substitution that reduces the ability 
of 82702 to bind the peptide can give the competitive edge 
to 88, though, and restore presentation of viral-derived 
antigen. 
Discussion 
MHC class I molecules select peptides according to the 
specificity of their binding grooves, and this is believed 
to be the major determinant in the selection of antigenic 
peptides for presentation. Indeed, class I molecules are 
highly involved in determining which peptides occur intra- 
cellularly (Rotzschke and Falk, 1991). Sequencing of pep- 
tides eluted from class I molecules from virally infected 
cells has shown that epitopes can only be detected in cells 
that express their restricting molecules (Falk et al., 1990) 
and it is thought that protection of these epitopes by bind- 
ing is the basis of such influence on the cellular peptide 
composition. Further, transfections of class I molecules 
from one species into the cells of another species allows 
presentation of both viral and allopeptides restricted by 
that allele (Wallny et al., 1992; Rotzschke et al., 1991; 
Lobigs and Mullbacher, 1993), demonstrating that the 
presence of the restricting allele alone is sufficient for the 
appropriate processing and presentation of antigens, even 
across the species barrier. It is, therefore, unusual (pro- 
vided that the processing and transport processes are in- 
tact) for a cell line that expresses the correct class I mole- 
cule to be unable to present an expected viral-derived 
epitope to CTL. 
In previous studies, we described the donor NW whose 
cells differed from other B2702-expressing cell lines in that 
they failed to present certain peptide epitopes, whereas 
the other cell lines did (Pazmany et al., 1992). The failure 
to present through 82702 extended to several expected 
epitopes and occurred either following viral infection or 
with the addition of peptide. These earlier studies estab- 
lished that the 82702 molecule of NW was of normal se- 
quence (Pazmany et al., 1992) and this along with data 
from other studies (Lopez et al., 1994; S. R.J., unpub- 
lished data), suggested that compared with 82702 mole- 
cules in other cells, the 82702 molecules in the cells of 
NW may be assembling with a different subset of peptides. 
In subsequent studies of antigen presentation through 
HLA-B8, the NW cell line failed to present an expected 
epitope from the influenza A nucleoprotein, although 
added peptide was presented normally (RowlandJones 
et al., 1993). The findings for antigen presentation through 
88 differ from those for 82702 in certain respects, though. 
First, the antigen presentation polymorphism through 
82702 extends to all family members carrying the HLA-A3 
82702 haplotype, while cells from the daughter of NW, 
who inherited the HLA-B8 haplotype, in the absence of 
the HLA-A3 82702 haplotype present NP 380-388 follow- 
ing viral infection normally. Second, the failure to present 
following viral infection through B8 appears to be specific 
for the NP 380-388 peptide. And, finally, the NW cell line 
can present NP 380-388 when exogenously delivered. 
Thus, it appeared as though the NW cell line was specifi- 
cally unable to generate the NP 380-388 peptide. If the 
same mechanism were responsible for the presentation 
polymorphisms through each of these alleles in NW and 
his family, then these data would suggest that a genetic 
factor, possibly linked to the HLA-A3 82702 haplotype, 
was modifying antigen processing, selection, or both in 
their cells. 
We now have investigated the molecular basis of the 
unusual properties associated with BB-restricted antigen 
presentation in the NW cell line and we find that, although 
we do not know the basis of the 82702 abnormality, differ- 
ent mechanisms are probably responsible for the proper- 
ties of each allele. Mapping of a B2702-restricted influenza 
A epitope revealed a cluster of epitopes in the nucleopro- 
tein, and within this cluster the 88 and 82702 epitopes 
overlap by 8 aa. Using a panel of B-LCL coexpressing 
B8 and 82702, we find that the NW phenotype (for 88 
presentation) extends to other cell lines expressing the 
allelic combination of 88 and 82702. Further using 
transfectants of the class l-reduced cell line, ClR, we 
have demonstrated that this phenotype can be recreated 
by coexpressing 88 and 82702 in the same cell. Because 
the inability to present NP 380-388 is a function of the 
allelic combination of the cell, it is likely to be due to an 
event in the ER and the overlapping epitopes suggests 
competition between the alleles for a common peptide 
fragment. Deng et al. (1993) have described a similar 
mechanism for MHC class II alleles, although in this in- 
stance the competition appeared to be for a longer peptide 
fragment that spanned two disparate epitopes. 
Several lines of evidence suggest that B8 has an appar- 
ent low affinity for the NP 380-388 peptide, even though 
it is an epitope that stimulates a vigorous CTL response 
in nearly all B&positive individuals. In our lysate binding 
assays, levels of peptide binding were, overall, low. For 
other class I-peptide systems (i.e., HLAA2 and Matrix 
58-88 or HLAA2 and HIV Pol), we can detect specific 
binding of peptide in the l-l 0 nmol range using this assay 
(Tussey et al., 1994). With B8 and the NP peptide, how- 
ever, we do not detect binding until the 100 nmol to 1 Frn 
range. Levels of peptide binding to B8 were also low in 
the transport assays and were approximately 38 to 40-fold 
lower than those seen with other class I-peptide systems. 
Two other lines of evidence support the idea that NP 380- 
388 has a relatively low affinity for 88. One is that the 
optimized 88 epitope does not titer past lO* M in CTL 
assays and is readily competed out by other 88 epitopes 
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(Sutton et al., 1993; S. R.J. and L. T., unpublished data). 
The other derives from in vitro binding assays where class 
I complexes are reconstituted from free class I heavy 
chains, ‘*%labeled 82, and peptide. The stability of these 
complexes can then be determined by monitoring p2 dis- 
sociation on nondenaturing IEF gels. In such assays, the 
tl/t2 dissociation for most A2 antigenic peptides was 16- 
50 hr (A2 and Matrix 56-66 was 50 hr; Parker et al., 1992). 
The tllt2 dissociation for B6 and NP 360-386, using this 
assay, however, is 2 hr (DiBrino et al., 1994). Our binding 
and transport studies further suggest that NP 360-386 
binds 82702 almost as well as B6, but if we introduce a 
mutation in the epitope that alters the relative ability of 
the peptide to bind each allele, presentation through 86 
is restored. Taken together, the data suggest that the con- 
sequence of the overlapping B6 and 82702 epitopes is 
that in a cell where both B6 and 82702 are assembling 
in the ER they compete for a common fragment, and this 
leads to suboptimal loading of 86. Thus, the failure of the 
NW cell line to present NP 360-386 is not due to any 
processing or selection polymorphism specific to the NW 
cell line, but rather to the fact that the cell coexpresses 
82702 and 86. This, of course, fails to explain the unsual 
properties associated with 82702 presentation in these 
cells. 
At first glance, it is difficult to imagine, given that sensiti- 
zation for CTL recognition probably only requires lOO- 
200 peptide-MHCcomplexes(Christinck et al., 1991), that 
competition for NP 360-366 by B2702 could actually be 
limiting for CTL recognition. Estimates of peptide copy 
numbers per cell, however, suggest that many peptides 
only occur at about 100-200 copies per cell (Rammensee 
et al., 1993). These estimates derive from analyses of 
class l-associated peptides and, as such, are a function 
of the ability of a given peptide not only to be processed 
but also on its ability to compete for translocation and then 
to compete for binding to its restricting allele. Thus, it is 
a series of processes and interactions that determines the 
number of complexes that are ultimately formed within the 
cell, and for many epitopes it appears that this number is 
just above the threshold required for CTL recognition. The 
NP 360-366 peptide is only a moderate competitor for 
translocation (Figure 5B), and this process could serve to 
limit the concentration of the peptide as it enters the ER. 
Peptides that are strong competitors for translocation 
characteristically have I& values in the range of 1 pM 
(Shepherd et al., 1993; Schumacher et al., 1994; Andro- 
lewicz and Cresswell, 1994). However, in NW cells NP 
360-366 has an IGO value of 30 PM, while the previously 
characterized 827 self-peptide (which is considered to be 
a strong competitor for translocation) has an IGO of 0.2 
pM. Certainly, other processes in the cytoplasm, such as 
processing of the epitope, or proteolysis of the peptide, 
could further serve to limit the concentration of this pep- 
tide. There is some evidence that limiting the availability 
of endogenously processed peptides can impair recogni- 
tion by CTL (Milligan et al., 1990). We also find that NP 
360-366 has an apparently low binding affinity for 86 (see 
above), and that this affinity is almost matched by that 
for 82702. Therefore, 82702 could compete almost as 
effectively as 86 for these limiting concentrations of NP 
360-366 in cells where they are simultaneously assem- 
bling, and this could lead to suboptimal loading of 86. 
Thus, we do not think that 82702 outcompetes B8 for the 
NP 380-366 peptide. But, rather, that there is a limiting 
amount of the NP peptide available for binding and that 
the simultaneous loading of this peptide onto 827 lowers 
the number of B&NP complexes formed to below the 
threshold required for CTL sensitization. It is important to 
stress that 86 loading is suboptimal rather than nonexis- 
tent. We have observed, using certain CTL lines or with 
prolonged (X5 hr) CTL assays, that the competition for 
NP 360-368 by 82702 is not absolute. Therefore, we know 
that some BB-NP 380-366 complexes are being formed 
in NW cells and reaching the cell surface; apparently, 
though, under most circumstances the number of com- 
plexes reaching the cell surface is below the threshold 
required for CTL recognition. There are factors that could 
contribute to a situation where 82702 actually does out- 
compete B8 for the NP 360-388 peptide. For instance, 
82702 could associate more efficiently with TAP than B8. 
Or for each allele NP 380-366 will be competing with a 
different pool of peptides for binding, and in this respect 
perhaps NP 380-388 competes relatively well for binding 
to 827 and less efficiently for binding to 88. At present, 
though, we favor the simpler model, whereby they both 
bind a peptide for which the concentration is limited. 
For proteins in which large numbers of CTL epitopes 
have been mapped, it is clear that epitopes are not ran- 
domly distributed throughout the protein. Instead, they 
tend to cluster, and a fair number of overlapping epitopes 
have been reported (Johnson et al., 1992; Nixon et al., 
1992; Elliott et al., 1993). This clustering may be due to 
the fact that most class I molecules bind peptides with 
hydrophobic anchors and often, because of structural and 
functional constraints, hydrophobic residues are clustered 
in proteins. Alternatively, it could reflect the proteolytic 
processes involved in the generation of antigenic pep- 
tides. It has been suggested that the secondary and ter- 
tiary structure of proteins may play a role in the generation 
of peptides, so that certain regions of the protein (de- 
pending on their orientation) are more effectively pro- 
cessed than others. The latter possibility would predict, 
though, that the position of the epitope in the protein would 
affect its ability to be generated. In at least one instance 
this seems to be the case (Del Val et al., 1991), although 
there are also instances where the position of the epitope 
has had no effect on the generation of the epitope (Chimini 
et al., 1989; Hahn et al., 1991). 
The data presented hereshow that overlapping epitopes 
can influence epitope selection, but whether they will do 
so in each case is not clear. The effect of other overlapping 
epitopes, if any, on the processing, selection, or both, of 
epitopes really depends on how antigenic peptides are 
produced, about which little is known. One model put forth 
by Rotzchke and Falk (1991) incorporates the observation 
that most H-2 class I peptide motifs have a hydrophobic 
C terminus, and suggests that this may reflect the specific- 
ity of the proteolytic enzymes involved in generating anti- 
genie peptides. With this model, the first step in antigen 
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processing is the generation of precursor fragments, vary- 
ing in length, but with common C termini. Fragmentsfulfill- 
ing specific binding requirements bind the appropriate 
class I and trimming at the N terminusoccurs. But, todate, 
there is little data as to the real nature of the fragments 
generated in the cytoplasm. Although TAP preferentially 
transports peptides of 8-l 1 aa, longer peptides are capa- 
ble of being transported (Momburg et al., 1994a; Andro- 
lewicz and Cresswell., 1994); small populations of class 
I molecules associated with long peptides have been de- 
scribed(Joyce et al., 1994; Urban et al., 1994). Thesesorts 
of data, although indirect, do suggest that the proteolytic 
machinery indiscriminantly processes peptides to varying 
length in the cytoplasm, but those peptides of appropriate 
length for class I binding are preferentially transported. 
Given that shorter fragments will be preferentially repre- 
sented in the ER, competition (at the level of binding) cre- 
ated by overlapping epitopes will probably be limited to 
epitopes of sufficient overlap as to be contained on a frag- 
ment of 8-l 1 aa. 
Experimental Procedures 
Subcloning of the HLA-Bg Gene 
HIA-f38 cDNA cloned into the EcoRl (5’)-BamHI (3’) site of Ml3 was 
the gift of Dr. C. Quinn. The 5’ EcoRl restriction enzyme site was 
changed to an Xhol site by first subcloning the cDNA into Bluescript 
(Stratagene). The gene was then subcloned into the Xhol-BamHI re- 
striction sites of PREP-4 (Invitrogen). 
Tranefections and Maintenance of Cell Lines 
HMyPCl R-82702 (Cl R-82702) cells were the gift of Dr. J. Lopez de 
Castro (Madrid, Spain). The HLA-B&PREP-4 construct was trans- 
fected into both the ClR and ClR-B2702 cell lines byelectroporation. 
For this, IO’cells were mixed with 20 rg of DNA in 0.5 ml of RPM 1640 
and electroporated using a gene (Bio-Rad Laboratories) electroporator 
set to 250 V and 500 pF. Cells were resuspended in 50 ml of RPM1 
1640 containing 10% fetal calf serum, 2 mM L-glutamine, 100 IUlml 
penicillin, and 100 @g/ml streptomycin (RIO) and plated in a 24-well 
plate. The next day, selective media containing 300 pglml hygromycin 
B (CalBiochem) was added. Cell surface expression of the transfected 
88 gene was determined by indirect immunofluorescence with Bw6 
(Radka et al., 1982) and fluorescein isothiocyanate-conjugated goat 
anti-mouse immunoglobulin G (IgG) followed by analytical flow cytome- 
try. Positive transfectants were maintained in 300 pg/ml hygromycin 
B. The HLA-Be-PREP-4 construct was introduced into CHO cells by 
electroporation with the electroporator set to 300 V and 960 PF. Cells 
were plated as described above, except the selective and maintenance 
media contained 1 mg/ml hygromycin B. The human B lymphoblastoid 
cell lines, NW, HW, and HR were maintained in RlO. 
Generatlon of CTL Lines 
Influenza-specific CTL lines were grown from peripheral blood mono- 
nuclear cells (PBMCs) as previously described (Gotch et al., 1987b; 
Nixon et al., 1988). They were maintained in culture by restimulation 
every lo-14 days with autologous irradiated (3000 rads) B-LCL, which 
had been pulsed for 1 hr with the appropriate peptide. The lines were 
cultured in RPM1 1640 (GIBCO) supplemented with 10% fetal calf 
serum (GIBCO) and 10 U/ml rat interleukin-2 (rlL-2) (Cetus Corpora- 
tion, Emeryville, California). 
Generatlon of CTL Clones 
Peptide-specific CTL clones were generated from established CTL 
lines by seeding at 0.3 or 1 cell/well in flat-bottomed (HW clones) or 
(AR or HR clones) round-bottomed 96-well microtiter plates (Nunc, 
GIBCO) in 100 ~1 of cloning mixture consisting of RlO containing mixed 
irradiated (3000 rads) PBMCs from three donors at a concentration 
of lo5 per well, autologous irradiated (3000 rads) B-LCL (peptide 
pulsed) at 1O’per well, and phytohematogglutinin at a final concentra- 
tion of 0.5 @ml. On day 4, an additional 100 pl of medium, supple- 
mented with 20% lymphocult-T (Biotest) was added. Clones were ex- 
panded to 24-well plates after 11-14 days in a further 1 ml of cloning 
mixture and tested for specific activity. Positive clones were main- 
tained in medium containing 10% lymphocult-T with weekly restimula- 
tions using autologous irradiated peptidepulsed B-LCLs. 
Generation of Recombinant Vaccinlae 
PurifiedoligonucleotidesencodingNPresidues374-391 (MESSTLEL- 
RSRYWAIRTR) or with the lysine substitution (MESSTLELKSRYWAI- 
RTR) were obtained from British Biotechnology (Oxford, England). 
These oligonucleotides included an Ncol site at the 5’end and a Bglll 
site at the 3’end. Sequences of the oligonucleotides are the following: 
oligo A, 5’-CATGGAAAGTAGT ACTCITGAAC’ITCGTAGTCGTTA’TT- 
GGG CTAlTCGTACTCGlTAGCTGACTAGA-3’ and its complemen- 
tary&and, oligo 0, Y-GATCTCTAGTCAGCTAA CGAGTACGAATAG- 
CCCPATAACG ACTACGAAGlTCAAGAGTACTACTT TC-3’; oligo C, 
5”CATGGAAAGTA GTACTCTTGAACnAAGAGTCGT-i’ATT GGGC- 
TATTCGTACTCGlTAGC TGACTAGA-3’ and its complementary 
strand, oligo D, LI-GATCTCTAGTCA GCTAACGAGTACGAATAGCC- 
CAATAACGACTCTTAAGTTCAAGAG TA CTAClTTC-3’. For the an- 
nealing of the single-stranded oligonucleotides, 100 pmol each of oligo 
A and B or oligo C and D was heated to 95OC for 10 min and allowed 
to cool slowly to room temperature. The resulting double-stranded 
inserts were ligated into the Ncol and Bglll sites of the transfer plasmid 
pSCl1. The transfer vector was introduced into wild-type vaccinia virus 
infectedTK- 143cellsusing lipofectin reagent (GIBCOBRL). Recombi- 
nant vaccinia were selected in the presence of BUdR and X-Gal. Re 
combinant plaques were taken through three rounds of purification. 
For overnight infections, 1 x lo* cells were infected with l-2 pfu per 
cell for 1 hr at 37OC. Cells were washed and incubated overnight in 
1 ml of culture medium. For daytime infections, 1 x 16 cells were 
infected with 3-5 pfu per cell for 1 hr at 37OC, washed, and incubated 
in 1 ml of culture medium for 3 hr. 
Viruses and Peptldes 
Influenza A virus AX/31 containing the NP gene from the 1934 AlPRl 
E/34 strain of influenza was grown in the allantoic sacs of 1 l-day-old 
embryonated chicken eggs. Vat-imp encodes residues 1,2,327-498 
of influenza A/NT/60/68 (Townsend et al., 1988). Peptides represent- 
ing NP sequences were synthesized either using a MilligenlBiosearch 
9500 automated peptide synthesizer and standard Merrifield &II?- 
butoxycarbonlyl chemistry (Dr. D. Klapper, University of North Care- 
lina, Chapel Hill, North Carolina) or a Zinser analytic automated pep 
tide synthesizer and standard 9-fluorenylmethoxycarbonyl chemistry. 
Peptides were high pressure liquid chromatography purified prior to 
use. 
CTL Assays 
Effector cells were tested for their ability to lyse Yr-labeled target 
cells in a standard 4 hr 5’Cr release assay. Target cells, either B-LCLs 
or ClR transfectants, were labeled with 100 pCi of Na&rO, for 1 hr 
at 37OC. Cells were washed twice in RlO and plated in wells of a 
round-bottomed 9&well plate at 5 x 103 cells/well in 150 pl with or 
without CTL. For peptide assays, peptide was added to a final concen- 
tration of lo-’ M for each well. For assays of AX/31, antigen presenta- 
tion targets were infected in serum-free medium with influenza virus 
l-2 HAU per 100 cells as described (Gotch et al., 1987a). For assays 
with recombinant vaccinia viruses, 1 x 10 cells were either infected 
with l-2 pfu/cell for 1 hr at 37OC, washed, and incubated overnight 
at 37“C in 1 ml of RlO or infected with 3-5 pfulcell for 90 min at 
37OC, washed, and incubated for 3 hr at 37OC. Chromium release 
was measured by harvesting 20 ~I of supernatant from each well onto 
a filtermat and counting in a p plate counter (LKB Instruments, Incorpc- 
rated, Gaitherburg, Maryland). The results are expressed as per cent 
specific lysis, which is calculated as follows: 
Percent of specific lysis = ([cpm,+ - cpm,,, I cpm,, - 
cpm,.,]) x 100 
Spontaneous release (cpm+,) is determined from targets incubated 
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with medium atone and maximal release (cpm-) is determined from 
targets incubated with 5% Triton X-100. 
lodlnatlons 
For the lysate binding assays, peptides were iodinated using a stan- 
dard chloramine T assay. Peptide (10 ug) in 100 ul of phosphate- 
buffered saline was incubated for 60 sat 26OC with 1 mCi of ‘la1 (Amer- 
sham) and 10 pl of chloramine T (5 ma/ml). The reaction was stopped 
by adding 30 ul of sodium metabisulfite (5 mg/ml) and 200 PI of 10 
mM Trls-HCI (pH 7.5) 0.15 M NaCI, 0.1% NP40,0.1% bovine serum 
albumin, and 0.02% sodium azide. Unbound iodine was removed by 
PassageoveraSephadexG-10spincolumn. Fortheintracellulartrans- 
port assays, peptides were iodinated as previously described (Andro- 
lewicz et al., 1993). 
Peptlde Bindlng Assays 
Peptide binding assays were performed essentially as previously de 
scribed (Tussey et al., 1994). In brief, IO7 cells were incubated for 45 
min at 37OC in methionine-free medium. FSjTrans-label (120 uCi) 
(Amersham) was added and the cells were incubated for 1 hr at 37OC. 
Cells were washed two times in phosphate-buffered saline then lysed 
in 1 ml of lysis buffer containing 20 mM Tris-HCI (pH 7.5) 150 mM 
NaCI, and 0.5% NP40. After 30 min on ice, &sates were cleared by 
centrifugation for IO min in a refrigerated microfuge. 1251-labeled pepttde 
was added, usually over the range of 2 x 1 v-6 x IO’ cpm, along 
with 90 ul of 10% Staphlococcus aureus immunoadsorbent. Based 
on the specific activity of the peptide, we estimate that with this range 
of cpm, labeled peptide was added to a final concentration of 50 nM 
to 2 uM in these assays. Samples were immunoprecipitated with 10 
ug of the human class l-specific antibody W6/32 (Barnstable et al., 
1976) and an excess of immunoadsorbent. lmmunoprecipitates were 
washed three times in lysis buffer and analyzed on a 15% NaDodS04- 
polyacrylamide gel under reducing conditions. Gels were quantitated 
using a phosphoimager and the results reported as the ratio of pixels 
contained in the peptide band to those contained in the heavy chain 
band. 
Assembly of HLA-B6 In CHO Cells 
Cells (6 x 103 were starved for 1 hr in 1 ml of methionine-free media. 
?6-Trans label (1.2 mCi) was added and cells were incubated at 37OC 
for l-2 hr. Cells were washed and lysed as above, except that the 
lysis buffer also contained 5 t.@ml human 62-microglobulin (Sigma). 
After 30 min on ice, lysates were cleared by centrifugation for 10 min 
in a refrigerated microfuge. The cleared lysate was aiiquoted among 
tubes containing varying concentrations of peptide. We added 90 pl 
of 10% Staphlococcus aureus immunoadsorbent and the samples 
were rocked overnight at 4OC. Samples were immunoprecipitated, 
analyzed, and quantitated as above. The results are reported as the 
number of pixels contained within the heavy chain band. 
Intracellular Lo8dlng and Transport Assays 
Permeabilixation of cells with streptolysin 0 and the intracellular load- 
ing assays were carried out as previously described (Androlewicz et 
al., 1993). In brief, 2 x 10’ cells were permeabilized and incubated 
with 2 x 10’ cpm of ‘LJI-labeled peptide. Based on the specific activity 
of the labeled peptide. the final conentration of peptide used in these 
assays is between 200 nM to 1 uM and is comparable to the concentra- 
tion of peptide used in the lysate binding assays. Peptide translocation 
was allowed to proceed for 10 min, cells were then washed and solubi- 
lized in 1 ml of buffer containing 1% Triton X-100,0.15 M NaCI, 9.01 M 
Tris-HCI (pH 7.4) 5 mM iodoacetamide, 0.5 mM phenylmethylsulfonyl 
fluoride, and 10 uM of the appropriate unlabeled peptide to prevent 
postsolubilization binding of thelabeled peptide. Lysateswereclarified 
by centrifugation at 10,000 x g for 5 min, immunoprecipitated with 
10 pg of W6/32 (Barnstable et al., 1976). and the level of bound peptide 
determined by counting in a y counter (LKB Compugamma CS). The 
peptide competition assays were essentially as previously described 
(Androlewicz and Cresswell, 1994). Basically, 10’ SLC-treated NW 
cells were incubated for 5 min at 37OC with various concentrations 
of unlabeled competitor peptides and ‘“1-827x3* (50 nM). B27#3’ 
(RRYQNSTEL) is avariant of a 827 self-peptide. which has an N-linked 
glycosylation acceptor site and has been previously characterized in 
these assays (Androlewicz and Cresswell. 1994). Cells were washed 
and solubilized as with the intracellufar loading assays. The glycosyl- 
ated ‘“I-B27#3’ peptide was Notated from the extracts using conca- 
navalin A-Sepharose beads (25 ul, 50% suspension, Sigma). Pellets 
were washed and counted in a y counter. 
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